Acute Lymphoblastic Leukemia News and Research

RSS

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.

UChicago Medicine working with Novartis to offer breakthrough gene therapy for pediatric ALL patients

The University of Chicago Medicine is one of a limited number of U.S. sites working to offer a breakthrough gene therapy for pediatric acute lymphoblastic leukemia (ALL), which was just approved by the U.S. Food and Drug Administration.

31 Aug 2017

FDA makes the first gene therapy Kymriah available for treatment of pediatric ALL

The U.S. Food and Drug Administration (FDA) has issued a press release making the first even gene therapy available for treatment of children with a form of acute lymphoblastic leukemia (ALL).

30 Aug 2017

$Novartis gets FDA approval for novel immunocellular therapy to treat relapsed or refractory B-cell ALL$

Novartis gets FDA approval for novel immunocellular therapy to treat relapsed or refractory B-cell ALL

Novartis announced today that the US Food and Drug Administration has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

30 Aug 2017

Pioneering cancer gene therapy gets green light — and $475,000 price tag

The country's first approved gene therapy — approved Wednesday to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment, its manufacturer announced.

30 Aug 2017

FDA approves first cell-based gene therapy for use in the United States

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases.

30 Aug 2017

FDA approves Besponsa – Pfizer’s new drug for rare form of acute lymphoblastic leukemia

The U.S. Food and Drug Administration (FDA) today approved Besponsa (inotuzumab ozogamicin) in the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) - a rare form of ALL.

17 Aug 2017

$FDA approval provides new, targeted treatment option for adults with relapsed or refractory B-cell ALL$

FDA approval provides new, targeted treatment option for adults with relapsed or refractory B-cell ALL

The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

17 Aug 2017

FDA approves fixed dose combination chemotherapy for subtypes of AML that have poor survival outcomes

The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.

3 Aug 2017

New analysis compares emerging algorithms that look for cancer mutations

Sanford Burnham Prebys Medical Discovery Institute has undertaken the first-ever comparative analysis of a newly emerging category of algorithms that mine genetic information in cancer databases by focusing on internal gene structure (subgene resolution algorithms), in contrast to classical approaches that focus on genes treated as single units.

17 Jul 2017

FDA panel recommends new breakthrough gene therapy for B-cell acute lymphoblastic leukemia (ALL)

A Food and Drug Administration (FDA) panel created history by recommending a gene therapy for patients with cancer. In this therapy the patient’s own genes would be modified to fight the cancer cells. The patient’s cells which are thus altered to treat the cancer would thus be termed as “living drugs” as they act as soldiers to treat the cancer. These cells boost up the immune system and help the body fight the cancer.

14 Jul 2017

ERYTECH partners with Queen’s University to advance its product candidate for treating arginase-1 deficiency

ERYTECH Pharma, a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Queen's University in Canada to advance the preclinical development of ERYTECH's eryminase program specifically for the treatment of arginase-1 deficiency, a rare and severe metabolic disorder related to arginine metabolism.

12 Jul 2017

First systematic genomic analysis of patients with T-ALL may aid development of new therapies

A consortium including St. Jude Children's Research Hospital and the Children's Oncology Group has performed an unprecedented genomic sequencing analysis of hundreds of patients with T-lineage acute lymphoblastic leukemia (T-ALL).

4 Jul 2017

New cancer drug shows promise to treat leukemia in mouse models

Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States. The blood cancer can affect both children and adults.

9 Jun 2017

Study finds steady decline in severe health problems for childhood cancer survivors

Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems occurring five or more years after diagnosis has declined over time.

5 Jun 2017

New trial aims to prolong remission for pediatric leukemia patients treated with T-cell immunotherapy

After phase 1 results of Seattle Children's Pediatric Leukemia Adoptive Therapy trial have shown T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia into complete initial remission, researchers have now opened a first-in-human clinical trial aimed at reducing the rate of relapse after the therapy, which is about 50 percent.

9 May 2017

Second cancers are far deadlier in younger people than older adults

Second cancers in children and adolescents and young adults are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients ages 15-39 overall, a new study by UC Davis researchers has found.

20 Apr 2017

NCCN Radiation Therapy Compendium adds nine new clinical practice guidelines in oncology

The National Comprehensive Cancer Network continues to build its NCCN Radiation Therapy Compendium with the publication of radiation therapy (RT) recommendations from an additional nine NCCN Clinical Practice Guidelines in Oncology

19 Apr 2017

Global inequalities in survival for childhood leukemia still persist in some countries, study finds

Although global inequalities in survival from childhood leukemia have narrowed, they still persist with five-year survival in some countries nearly twice as high as in others for children diagnosed during 2005-2009, according to a study published in The Lancet Haematology.

13 Apr 2017

Activation of specific protein could lead to acute lymphoblastic leukemia, study reveals

The discovery of a protein signature that is highly predictive of leukemia could lead to novel treatments of the leading childhood cancer, according to new study showing that competition among certain proteins causes an imbalance that leads to leukemia.

11 Apr 2017

Researchers discover how epigenetic lesion can lead to T-cell acute lymphoblastic leukemia

Researchers from the Epigenetics and Cancer Biology Program led by Dr. Manel Esteller at the Bellvitge Biomedical Research Institute have discovered how an epigenetic lesion can lead to T-cell acute lymphoblastic leukemia.

30 Mar 2017

Acute Lymphoblastic Leukemia News and Research

Further Reading

UChicago Medicine working with Novartis to offer breakthrough gene therapy for pediatric ALL patients

FDA makes the first gene therapy Kymriah available for treatment of pediatric ALL

Novartis gets FDA approval for novel immunocellular therapy to treat relapsed or refractory B-cell ALL

Pioneering cancer gene therapy gets green light — and $475,000 price tag

FDA approves first cell-based gene therapy for use in the United States

FDA approves Besponsa – Pfizer’s new drug for rare form of acute lymphoblastic leukemia

FDA approval provides new, targeted treatment option for adults with relapsed or refractory B-cell ALL

FDA approves fixed dose combination chemotherapy for subtypes of AML that have poor survival outcomes

New analysis compares emerging algorithms that look for cancer mutations

FDA panel recommends new breakthrough gene therapy for B-cell acute lymphoblastic leukemia (ALL)

ERYTECH partners with Queen’s University to advance its product candidate for treating arginase-1 deficiency

First systematic genomic analysis of patients with T-ALL may aid development of new therapies

New cancer drug shows promise to treat leukemia in mouse models

Study finds steady decline in severe health problems for childhood cancer survivors

New trial aims to prolong remission for pediatric leukemia patients treated with T-cell immunotherapy

Second cancers are far deadlier in younger people than older adults

NCCN Radiation Therapy Compendium adds nine new clinical practice guidelines in oncology

Global inequalities in survival for childhood leukemia still persist in some countries, study finds

Activation of specific protein could lead to acute lymphoblastic leukemia, study reveals

Researchers discover how epigenetic lesion can lead to T-cell acute lymphoblastic leukemia

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News